华润医药(03320.HK)附属完成发行30亿元中期票据

Core Viewpoint - China Resources Pharmaceutical (03320.HK) has successfully issued the first phase of its 2025 medium-term notes, raising a total of RMB 3 billion with a maturity of three years and an annual interest rate of 2.19 [1] Group 1 - The first phase of the 2025 medium-term notes has been issued by China Resources Pharmaceutical's non-wholly owned subsidiary, China Resources Pharmaceutical Commercial Group [1] - The total amount raised from the issuance is RMB 3 billion [1] - The funds raised will be used to repay interest-bearing debts of China Resources Pharmaceutical Commercial or its subsidiaries [1]